AN UPDATE DATA ON THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (review of literature)
Roman A. Gapeshin,
Evgeny R. Barantsevich,
Dmitry I. Rudenko,
Oksana V. Posokhina,
Tima R. Stuchevskaya https://doi.org/10.24884/1607-4181-2019-26-1-9-19
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous immune-mediated peripheral neuropathy with progressive or relapse-remitting course. Incidence of CIDP ranged between 1 and 8.9/100 000. Recently, most frequent therapies for CIDP treatment was glucocorticosteroids, intravenous immunoglobulin and plasma exchange. In cases of ineffectiveness or lack of effectiveness, cytostatics, monoclonal antibodies and others could be used for CIDP treatment. In the article, authors presented an update data on the use of main methods for CIDP therapy, their mechanisms of action, indication for their use and advantages and disadvantages of each of them.
About the Authors
Roman A. Gapeshin
Pavlov University
Russian Federation
Russian Federation
6-8 L’va Tolstogo street, St. Petersburg, 197022
Evgeny R. Barantsevich
Pavlov University
Russian Federation
Russian Federation
6-8 L’va Tolstogo street, St. Petersburg, 197022
Dmitry I. Rudenko
Pavlov University
Russian Federation
Russian Federation
6-8 L’va Tolstogo street, St. Petersburg, 197022
Oksana V. Posokhina
Pavlov University
Russian Federation
Russian Federation
6-8 L’va Tolstogo street, St. Petersburg, 197022
Tima R. Stuchevskaya
Pavlov University
Russian Federation
Russian Federation
6-8 L’va Tolstogo street, St. Petersburg, 197022
References
1. Bril V., Blanchette C. M., Noone J. M. et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016;30(7):1401– 1407. http://dx.doi.org/10.1016/j.jdiacomp.2016.05.007.
2. Laughlin R. S., Dyck P. J., Melton L. J. et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73(1):39–45.
3. Lefter S., Hardiman O., Ryan A.M. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. 2017;88(3):304–313.
4. Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go Clinical Presentation: One or More. J Peripher Nerv Syst. 2014;13:2–13.
5. Tursynov N. I., Grigolashvili M. A., Iluyshina N. Yu. et al. Modern aspects of diagnosis and treatment of chronic demyelinated polyneuropathies. Neurosurgery and Neurology of Kazahstan. 2016;3(44):38–45. (In Russ.).
6. Roux T., Debs R., Maisonobe T. et al. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. J Peripher Nerv Syst. 2018. http://dx.doi.org/10.1111/nep.12287.
7. Press R., Hiew F. L., Rajabally Y. A. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: Evidence base and clinical practice. Acta Neurol Scand. 2016;133(4):228–238.
8. Czock D., Keller F., Rasche F. M. et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.
9. Strehl C., Buttgereit F. Optimized glucocorticoid therapy: Teaching old drugs new tricks. Mol Cell Endocrinol. 2013;380 (1– 2): 32–40. http://dx.doi.org/10.1016/j.mce.2013.01.026.
10. Kleyman I., Brannagan T.H. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy. Curr Neurol Neurosci Rep. 2015;15(7).
11. Nobile-Orazio E., Gallia F., Terenghi F., Bianco M. Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan. Expert Rev Neurother. 2017;17(8):755–765. https://doi.org/10.1080/14737175.2017.1340832.
12. Schaik I.N., Eftimov F., van Doorn P. A. et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245–253.
13. Muley S. A., Kelkar P., Parry G. J. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With Pulsed Oral Steroids. Arch. Neurol. 2008;65(11):1460–1464. Doi: 10.1001/archneur.65.11.1460
14. Börü Ü.T., Erdoǧan H., Alp R. et al. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-Year follow up. Clin Neurol Neurosurg. 2014; 118:89–93.
15. Lieverloo G. G. A., Peric S., Doneddu P. E. et al. Cortico steroids in chronic inflammatory demyelinating polyneuropathy: A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol. 2018;265(9):2052–2059. http://dx.doi.org/10.1007/s00415-018-8948-y.
16. Dalakas M. C. Potential biomarkers for monitoring therapeutic response in patients with CIDP. J Peripher Nerv Syst. 2011;16(Suppl. 1):63–67.
17. Lünemann J. D., Nimmerjahn F., Dalakas M. C. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–89. Available at: http://www.nature.com/doifinder/10.1038/nrneurol.2014.253 (accessed 12.05.2019).
18. Van den Bergh P. Y. K., Hadden R. D. M., Bouche P. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher. Eur J Neurol [Internet]. 2010;17(3):356–363. http://doi.wiley.com/10.1111/j.1468-1331.2009.02930.x.
19. Lunn M. P., Ellis L., Hadden R. D. et al. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst. 2016;21(1):33–37.
20. Iijima M., Yamamoto M., Hirayama M. et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology. 2005;64(8):1471–1475.
21. Finsterer J., Aliyev R. Chronic inflammatory demyelinating polyneuropathy variant with creatine-kinase elevation and vanishing effect of immunoglobulins. Am J Case Rep. 2017;18:834–838.
22. Hughes R. A. C., Donofrio P., Bril V. et al. Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–144.
23. Magda P., Latov N., Brannagan T. H. et al. Comparison of Electrodiagnostic Abnormalities and Criteria in a Cohort of Patients with Chronic Inflammatory Demyelinating Polyneuropathy. Arch Neurol. 2003;60(12):1755–1759.
24. Latov N., Deng C., Dalakas M. C. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2010;67(7):802–807.
25. Kuwabara S., Misawa S., Mori M. et al. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: A five year follow up of 38 cases. J Neurol Neurosurg Psychiatry. 2006;77(1):66–70.
26. Katzberg H. D., Rasutis V., Bril V. Home IVIG for CIDP: a focus on patient centred care. Can J Neurol Sci. 2013;40(3):384–388.
27. Kuitwaard K., Hahn A. F., Vermeulen M. et al. Intravenous immunoglobulin response in treatmentnaïve chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2015;86(12):1331–1336.
28. Ritter C., Bobylev I., Lehmann H. C. Chronic inflammatory demyelinating polyneuropathy (CIDP): Change of serum IgG dimer levels during treatment with intravenous immunoglobulins. J Neuroinflammation [Internet]. 2015;12(1):1–8. Available at: http://dx.doi.org/10.1186/s12974-015-0361-1 (accessed 12.05.2019).
29. Grimm A., Vittore D., Schubert V. et al. Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP. J Neurol. 2016;263(6):1074–1082.
30. Vucic S., Black K., Baldassari L. E. et al. Long-term effects of intravenous immunoglobulin in CIDP. Clin Neurophysiol. 2007;118(9):1980–1984.
31. Nakanishi T., Suzuki N., Kuragano T. et al. Current topics in therapeutic plasmapheresis. Clin Exp Nephrol. 2014;18(1):41–49.
32. Tombak A., Uçar M.A., Akdeniz A. et al. Therapeutic Plasma Exchange in Patients with Neurologic Disorders: Review of 63 Cases. Indian J Hematol Blood Transfus. 2017; 33(1):97–105.
33. Szczepiorkowski Z. M., Winters J. L., Bandarenko N. et al. Guidelines On the Use Of Therapeutic Apheresis In Clinical Practice-Evidence Based Approach from the Apheresis Applications Committee of the American Society of Apheresis. Journl of Clinical Apheresis. 2010; (25):83–177.
34. Dyck P. J., Daube J., O’Brian P. et al. Plasma Exchange in Chronic Inflammatory Demyelinating Polyneuropathy. The New England Journal of Medicine. 1986;314(8):461–465.
35. Hahn A. F., Bolton C. F., Pillay N. et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119(4):1055–1066. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8813270 (accessed 12.05.2019).
36. SinanovićO., ZukićS., Burina A. et al. Plasmapheresis in neurological disorders: six years experience from Uni versity Clinical center Tuzla. F1000Research [Internet]. 2017;6:1234. Available at: https://f1000research.com/articles/6-1234/v1 (accessed 12.05.2019).
37. Vogl U., Leitner G., Dal-Bianco A. et al. Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation. Wien Klin Wochenschr. 2016;128(9–10):384–386.
38. Order of Ministry of Health of Russian Federation from 24.12.2012 no 1537n «About standart of specialized medical help to patients with chronic inflammatory demyelinating polyneuropathy confirmation».(In Russ.).
39. Nobile-Orazio E., Cocito D., Jann S. et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015;86(7):729–734.
40. Viala K., Maisonobe T., Stojkovic T. et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(1):50–56.
41. Doneddu P. E., Cocito D., Manganelli F. et al. Atypical CIDP: Diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2018;1:1–8.
42. Rabin M., Mutlu G., Stojkovic T. et al. Chronic inflammatory demyelinating polyradiculoneuropathy: Search for factors associated with treatment dependence or successful withdrawal. J Neurol Neurosurg Psychiatry. 2014;85(8):899–904.
43. Dyck P. J., Litchy W. J., Kratz K. M. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol [Internet]. 1994;36(6):838–845. Available at: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&AN=24370922 (accessed 12.05.2019).
44. Kaplan A., Brannagan T.H. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve. 2017;55(4):476–482.
45. Mahdi-Rogers M., Mccrone P., Hughes R.A.C. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014;21(1):34–9.
46. Blackhouse G., Xie F., Gaebel K. et al. Cost-Utility of Intravenous Immunoglobulin (Ivig) Compared With Corticosteroids for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Value Heal [Internet]. 2009;12(7):A380–A381. Available at: http://linkinghub.elsevier.com/retrieve/pii/S1098301510748737 (accessed 12.05.2019)..
47. Cocito D., Grimaldi S., Paolasso I. et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011;18(12):1417–1421.
48. Mahdi-Rogers M., Brassington R., Gunn A. A. et al. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (Review). Cochrane Database of Systematic Reviews. 2017;(5) (CD003280). http://dx.doi.org/10.1002/14651858.CD003280.pub5.
49. Velardo D., Riva N., Del Carro U. et al. Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. J Neurol. 2017;264(5):1011–1044.
50. Zhang Z., Zhang Z. Y., Fauser U., Schluesener H. J. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol. 2008;210(2):681–690.
51. Hughes R., Dalakas M. C., Merkies I. et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurol. 2018;17(8):689–698.
Review
For citations:
Gapeshin R.A., Barantsevich E.R., Rudenko D.I., Posokhina O.V., Stuchevskaya T.R. AN UPDATE DATA ON THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (review of literature). The Scientific Notes of the Pavlov University. 2019;26(1):9-19. (In Russ.) https://doi.org/10.24884/1607-4181-2019-26-1-9-19
Views:
1309
Email this article 